Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00048854 · ClinicalTrials.gov registry record · Phase 1

Antidepressant Treatment for Premenstrual Syndrome and Premenstrual Dysphoric Disorder

A Phase 1 study of Premenstrual Syndrome, sponsored by Yale University.

Completed
Registry status
Phase 1
Development phase
66
Enrollment target
1
Study location

NCT00048854 is a Phase 1 study of Premenstrual Syndrome that has completed, run by Yale University. The registered enrollment target is 66 participants, below the 124-participant average among 6 other Premenstrual Syndrome trials with a reported enrollment target (47% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00048854, a Phase 1 study of Premenstrual Syndrome, has completed, sponsored by Yale University.

COMPLETED
Registry status
Phase 1
Development phase
66 participants
Enrollment target
1
Study location

Study Summary

This study will determine whether characteristics of women with Premenstrual Syndrome influence response to treatment with serotonin reuptake inhibitors and whether SRIs can alleviate premenstrual symptoms.

Conditions Studied

Interventions

  • DRUG Sertraline
  • OTHER Treatment as usual (TAU)

Study Locations (1)

Connecticut

  • Yale School of Medicine - New Haven

Trial Details

FieldValue
Enrollment Target 66 participants
Start Date 2001-09
Est. Completion 2008-01
Phase Phase 1

Sponsor

Yale University

1,492 total trials

What the Registry Record Tells You About NCT00048854

The ClinicalTrials.gov registry entry for NCT00048854 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 124-participant average among 6 other Premenstrual Syndrome trials with a reported enrollment target (47% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Premenstrual Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Sertraline is the first listed.

NCT00048854 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.

Frequently Asked Questions

What is clinical trial NCT00048854 about?

NCT00048854 is a clinical study titled "Antidepressant Treatment for Premenstrual Syndrome and Premenstrual Dysphoric Disorder". This study will determine whether characteristics of women with Premenstrual Syndrome influence response to treatment with serotonin reuptake inhibitors and whether SRIs can alleviate premenstrual symptoms.

What is the current status of trial NCT00048854?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2001-09. Estimated completion is 2008-01.

What conditions does trial NCT00048854 study?

This clinical trial studies the following conditions: Premenstrual Syndrome.

What interventions are being tested in trial NCT00048854?

The interventions under investigation include: Sertraline (DRUG), Treatment as usual (TAU) (OTHER).

Who is sponsoring clinical trial NCT00048854?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00048854 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Premenstrual Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.